EZH2 and prostate carcinoma: The EZH2-DNMT dependent mechanism at least in prostate cancer suggest that targeting this pathway through specific inhibitors resulting in general epigenetic re-programming including up-regulation of ID4 could be a strong therapeutic strategy.